-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Axogen, Raises Price Target to $60

Benzinga·10/29/2026 14:58:11
Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $50 to $60.